Cytokinetics Inc is a biopharmaceutical company based in South San Francisco, California, dedicated to the development and potential commercialization of muscle activators and inhibitors for treating serious diseases. With a focus on small molecule drug candidates, Cytokinetics is advancing a diverse portfolio, including treatments for heart failure and hypertrophic cardiomyopathy. Their leading drugs in development, such as omecamtiv mecarbil and aficamten, are in late-stage clinical trials, showcasing the company's commitment to addressing unmet medical needs in muscle function and contractility.
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the…
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs,…
Tuesday's top analyst upgrades and downgrades included Array Technologies, CarMax, Caterpillar, Cleveland-Cliffs, Eaton, First Solar, Intercontinental Exchange, Medical Properties Trust, Paramount Global and Tesla.
Wednesday's top analyst upgrades and downgrades included Apple, Boston Scientific, Caterpillar, Ciena, Costco Wholesale, Generac, Hasbro, Rivian Automotive, Steel Dynamics, Tapestry, Trade Desk and Walmart.
Tuesday's top analyst upgrades and downgrades included Bank of New York Mellon, Cloudflare, Consolidated Edison, Ford, IBM, Incyte, Simon Properties and Skechers.
Here's the Thursday afternoon edition of analysts' upgrades, downgrades and price target changes on several popular stocks.
